| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S16066 R66673 |
Christensen (Carbamazepine) (All indications) (Controls exposed to LTG), 2024 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
1.30 [1.09;1.55] C excluded (control group) |
198/3,424 395/8,756 | 593 | 3,424 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S16019 R66498 |
Christensen (Carbamazepine) (All indications) (Controls unexposed, general population), 2024 | Low birth weight (<2500 g) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 1.46 [1.25;1.71] | 198/3,424 141,442/4,467,848 | 141,640 | 3,424 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18076 R76123 |
Leite (Carbamazepine) (Epilepsy), 2024 | Low birth weight | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free | Adjustment: No | 2.42 [0.86;6.77] | -/29 111/492 | - | 29 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9776 R34958 |
Coste (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.15 [0.79;1.67] C excluded (control group) |
35/502 179/2,916 | 214 | 502 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9777 R34976 |
Coste (Carbamazepine) (Controls unexposed, NOS) (Mixed indications), 2020 | Weight at birth <2500 g | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.26 [0.87;1.81] C | 31/468 91,172/1,707,707 | 91,203 | 468 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9743 R34761 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) b, 2013 | Low birth weight (< 2500 grams) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.30 [0.38;4.46] C excluded (control group) |
5/67 6/103 | 11 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9745 R34780 |
Veiby (Carbamazepine) (Controls unexposed, disease free) b, 2013 | Low birth weight (< 2500 grams) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: Yes |
1.80 [0.70;4.40] excluded (control group) |
5/67 5,024/106,899 | 5,029 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9746 R34794 |
Veiby (Carbamazepine) (Controls unexposed, sick) b, 2013 | Low birth weight (< 2500 grams) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 1.86 [0.66;5.27] C | 5/67 16/386 | 21 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9669 R34418 |
Kini (Carbamazepine) (Controls unexposed, sick), 2006 | Birth weight <2500 g | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No | 0.27 [0.07;1.00] C | 3/94 11/101 | 14 | 94 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.35 [0.96;1.90] | 232,878 | 4,082 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Carbamazepine) (All indications) (Controls unexposed, general population; 2: Carbamazepine) (Epilepsy; 3: Carbamazepine) (Controls unexposed, NOS) (Mixed indications; 4: Carbamazepine) (Controls unexposed, sick) ; 5: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.6258 (by Egger's regression)
slope=0.4178 (0.1668); intercept=-0.5639 (1.0415); t=0.5414; p=0.6258
excluded 9743, 9745, 9776, 16066